BR112020004489A2 - proteínas de ligação ao nkg2d, cd16 e um antígeno associado a tumor - Google Patents

proteínas de ligação ao nkg2d, cd16 e um antígeno associado a tumor Download PDF

Info

Publication number
BR112020004489A2
BR112020004489A2 BR112020004489-0A BR112020004489A BR112020004489A2 BR 112020004489 A2 BR112020004489 A2 BR 112020004489A2 BR 112020004489 A BR112020004489 A BR 112020004489A BR 112020004489 A2 BR112020004489 A2 BR 112020004489A2
Authority
BR
Brazil
Prior art keywords
seq
variable domain
binding site
amino acid
antigen
Prior art date
Application number
BR112020004489-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Gregory P. Chang
Ann F. Cheung
William Haney
Bradley M. LUNDE
Bianka Prinz
Asya Grinberg
Original Assignee
Dragonfly Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics, Inc. filed Critical Dragonfly Therapeutics, Inc.
Publication of BR112020004489A2 publication Critical patent/BR112020004489A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112020004489-0A 2017-09-07 2018-09-07 proteínas de ligação ao nkg2d, cd16 e um antígeno associado a tumor BR112020004489A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762555110P 2017-09-07 2017-09-07
US62/555,110 2017-09-07
US201762566824P 2017-10-02 2017-10-02
US62/566,824 2017-10-02
PCT/US2018/050073 WO2019051308A1 (en) 2017-09-07 2018-09-07 NKG2D, CD16 BINDING PROTEINS AND ANTIGEN ASSOCIATED WITH A TUMOR

Publications (1)

Publication Number Publication Date
BR112020004489A2 true BR112020004489A2 (pt) 2020-09-08

Family

ID=65634405

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020004489-0A BR112020004489A2 (pt) 2017-09-07 2018-09-07 proteínas de ligação ao nkg2d, cd16 e um antígeno associado a tumor

Country Status (13)

Country Link
US (3) US20200277383A1 (enExample)
EP (2) EP3925976A1 (enExample)
JP (4) JP7431392B2 (enExample)
KR (3) KR20240167101A (enExample)
CN (3) CN113004417A (enExample)
AU (3) AU2018329937B2 (enExample)
BR (1) BR112020004489A2 (enExample)
CA (2) CA3112984A1 (enExample)
IL (2) IL273067A (enExample)
MX (2) MX420258B (enExample)
RU (1) RU2021110369A (enExample)
SG (2) SG10202102502VA (enExample)
WO (1) WO2019051308A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3511340B1 (en) 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
EP3579848B1 (en) 2017-02-08 2024-10-30 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
JP7685821B2 (ja) 2017-02-20 2025-05-30 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質
BR112020015994A2 (pt) * 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
MX2020008336A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
JP7353576B2 (ja) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
EA202091977A1 (ru) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
SG11202101298XA (en) 2018-08-08 2021-03-30 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and a tumor-associated antigen
EA202190468A1 (ru) 2018-08-08 2021-07-06 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
WO2020086758A1 (en) 2018-10-23 2020-04-30 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins
MX2021006430A (es) 2018-12-03 2021-09-14 Agensys Inc Composiciones farmacéuticas que comprenden conjugados de fármaco-anticuerpo anti-191p4d12 y métodos de uso de las mismas.
US20220402998A1 (en) * 2019-10-30 2022-12-22 The Texas A&M University System Protease switch for dual targets chimeric antigen receptor t cell therapy
AU2021260960A1 (en) * 2020-04-22 2022-11-24 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
AR122018A1 (es) 2020-05-06 2022-08-03 Dragonfly Therapeutics Inc Proteínas que se unen a nkg2d, cd16 y clec12a
KR20230091885A (ko) * 2020-09-17 2023-06-23 어젠시스 인코포레이티드 191p4d12 단백질에 결합하는 항체 약물 접합체(adc)로 암을 치료하는 방법
CN117222663A (zh) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
CN113563474B (zh) * 2021-06-11 2023-05-02 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） EpCAM-CD16-NKG2D三特异性抗体及其应用
EP4388103A1 (en) * 2021-08-20 2024-06-26 Tallac Therapeutics, Inc. Nectin-4 antibodies and conjugates
JP2024537779A (ja) * 2021-09-29 2024-10-16 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及びｂａｆｆ－ｒに結合するタンパク質
KR20230060546A (ko) * 2021-10-22 2023-05-04 상트네어바이오사이언스 주식회사 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
CN120754270A (zh) * 2022-07-25 2025-10-10 艾更斯司股份有限公司 用特定抗体药物偶联物与帕博利珠单抗组合治疗癌症

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038339A1 (en) * 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
JP2003111595A (ja) * 2001-06-25 2003-04-15 Kyogo Ito 腫瘍抗原
CN1812999A (zh) * 2003-05-31 2006-08-02 麦克罗梅特股份公司 包含EpCAM特异构建体的药物组合物
WO2007002905A1 (en) * 2005-06-29 2007-01-04 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
JP5512128B2 (ja) 2005-12-08 2014-06-04 メダレックス・リミテッド・ライアビリティ・カンパニー フコシルｇｍ１に対するヒトモノクローナル抗体および抗フコシルｇｍ１を使用するための方法
US20110301056A1 (en) 2008-12-12 2011-12-08 Oncotherapy Science, Inc. Nectin-4 for target genes of cancer therapy and diagnosis
US8309093B2 (en) 2009-03-06 2012-11-13 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 24P4C12 proteins
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
ES2536996T3 (es) * 2009-07-06 2015-06-01 F. Hoffmann-La Roche Ag Anticuerpos biespecíficos de unión a digoxigenina
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN105567717B (zh) 2010-09-29 2019-10-29 艾更斯司股份有限公司 结合于191p4d12蛋白的抗体药物偶联物(adc)
CN107903325B (zh) * 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
JP6571527B2 (ja) 2012-11-21 2019-09-04 ウーハン ワイゼットワイ バイオファルマ カンパニー リミテッドＷｕｈａｎ Ｙｚｙ Ｂｉｏｐｈａｒｍａ Ｃｏ．， Ｌｔｄ． 二重特異性抗体
JP2016509014A (ja) * 2013-02-08 2016-03-24 ステムセントリックス， インコーポレイテッド 新規の多特異的構成物
SG11201600310QA (en) * 2013-07-16 2016-02-26 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
CA2925677A1 (en) * 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Bispecific her2 antibodies and methods of use
US11208497B2 (en) 2013-12-23 2021-12-28 Zymeworks Inc. Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof
AU2016206707A1 (en) 2015-01-14 2017-08-10 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
EP3258967A4 (en) 2015-02-20 2018-10-03 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
EP3347048B1 (en) 2015-09-09 2020-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
EP3579848B1 (en) * 2017-02-08 2024-10-30 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
MX2020008336A (es) * 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
CN117222663A (zh) * 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
US20230416402A1 (en) * 2022-03-03 2023-12-28 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2

Also Published As

Publication number Publication date
JP2023166409A (ja) 2023-11-21
EP3679071A1 (en) 2020-07-15
AU2021201494A1 (en) 2021-03-25
CN119735693A (zh) 2025-04-01
KR20210030503A (ko) 2021-03-17
KR20200044957A (ko) 2020-04-29
RU2020112333A (ru) 2021-10-08
MX420258B (es) 2025-02-10
MX2021002970A (es) 2021-05-12
JP2021098733A (ja) 2021-07-01
JP2020533311A (ja) 2020-11-19
IL273067A (en) 2020-04-30
JP2025093943A (ja) 2025-06-24
IL281323A (en) 2021-04-29
WO2019051308A1 (en) 2019-03-14
MX2020002626A (es) 2020-10-07
RU2021110369A (ru) 2021-06-01
AU2018329937A1 (en) 2020-03-19
US20210292420A1 (en) 2021-09-23
EP3679071A4 (en) 2021-06-09
CN113004417A (zh) 2021-06-22
CA3112984A1 (en) 2019-03-14
CA3074840A1 (en) 2019-03-14
SG11202001930QA (en) 2020-04-29
AU2024278313A1 (en) 2025-01-09
JP7431392B2 (ja) 2024-02-15
US20200277383A1 (en) 2020-09-03
US20230357409A1 (en) 2023-11-09
CN111315782A (zh) 2020-06-19
SG10202102502VA (en) 2021-04-29
AU2018329937B2 (en) 2024-09-12
EP3925976A1 (en) 2021-12-22
KR20240167101A (ko) 2024-11-26

Similar Documents

Publication Publication Date Title
US20230357409A1 (en) Proteins binding nkg2d, cd16 and nectin4
ES2986967T3 (es) Combinaciones de dominios variables de anticuerpos dirigidas al receptor NKG2D
AU2018220736B2 (en) Proteins binding HER2, NKG2D and CD16
US20200277384A1 (en) Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1)
US20200216544A1 (en) Proteins binding nkg2d, cd16, and egfr, hla-e, ccr4, or pd-l1
BR112021002278A2 (pt) proteínas que ligam nkg2d, cd16 e um antígeno associado a tumor
BR112019017758A2 (pt) proteínas multispecíficas de ligação ao alvo caixa, ano1, mesotelina, trop2, cea ou claudin-18.2
BR112020003654A2 (pt) proteínas de ligação ao nkg2d, cd16 e a um antígeno associado a tumor
BR112019017277A2 (pt) proteínas de ligação a cd33, nkg2d e cd16
BR112019016424A2 (pt) proteínas de ligação a bcma, nkg2d e cd16
BR112019024620A2 (pt) Ligante de proteína nkg2d, cd16 e antígeno associado a tumor
US20200024353A1 (en) Proteins binding psma, nkg2d and cd16
CA3070986A1 (en) Proteins binding nkg2d, cd16 and flt3
US20200002436A1 (en) Proteins binding cd123, nkg2d and cd16
BR112019017256A2 (pt) proteínas de ligação gd2, nkg2d e cd16
RU2816716C2 (ru) Белки, связывающие NKG2D, CD16 и опухолеассоциированный антиген
BR112019016315A2 (pt) Proteínas de ligação multiespecíficas para ativação de células natural killer e usos terapêuticos destas para tratamento de câncer

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]